Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

Summary

The study is to evaluate the safety, tolerability and whether there is an immune system response to multiple doses of ACC-001 with or without the use of a substance that may increase the response to the drug.

Timeline

Start

2008-12

Primary completion

2012-07

Completion

2012-07

Publications

• Arai H, Suzuki H, Yoshiyama T. Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies. Curr Alzheimer Res. 2015;12(3):242-54. doi: 10.2174/1567205012666150302154121.

Drugs

Indications